Akorn Reaches $24M Deal To End Investors' Accounting Suit
Specialty drugmaker Akorn Inc. has reached a $24 million deal to settle a proposed investor class action alleging that the company's failure to fix widespread accounting problems and weak internal controls...To view the full article, register now.
Already a subscriber? Click here to view full article